Company
Headquarters: Guangzhou, China
Employees: 32,337
CN¥19.50 Billion
CNY as of July 1, 2025
US$2.72 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. The company was founded in 1999 and is based in Guangzhou, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥26.70 B |
| EBITDA | CN¥1.55 B |
| Gross Profit TTM | CN¥9.11 B |
| Profit Margin | 3.66% |
| Operating Margin | 9.96% |
| Quarterly Revenue Growth | 3.00% |
DaShenLin Pharmaceutical Group Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603233 wb_incandescent